Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 347

The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.

Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer

Open access
Garaud, Soizic, Buisseret, Laurence, Solinas, Cinzia, Gu-Trantien, Chunyan, de Wind, Alexandre, Van den Eynden, Gert, Naveaux, Celine, Lodewyckx, Jean-Nicolas, Boisson, Anaïs, Duvillier, Hughes, Craciun, Ligia, Ameye, Lieveke, Veys, Isabelle, Paesmans, Marianne, Larsimont, Denis, Piccart-Gebhart, Martine, Willard-Gallo, Karen·2019·JCI Insight

Abstract

Tumor-infiltrating B-cells (TIL-B) in breast cancer (BC) have previously been associated with improved clinical outcomes; however, their role(s) in tumor immunity is not currently well known. This study confirms and extends the correlation between higher TIL-B densities and positive outcomes through an analysis of HER2-positive and triple-negative BC patients from the BIG 02-98 clinical trial (10yr mean follow-up). Fresh tissue analyses identify an increase in TIL-B density in untreated primary BC compared to normal breast tissues, which is associated with global, CD4+ and CD8+ TIL, higher tumor grades, higher proliferation and hormone receptor negativity. All B-cell differentiation stages are detectable but significant increases in memory TIL-B are consistently present. BC with higher infiltrates are specifically characterized by germinal center TIL-B, which in turn are correlated with TFH TIL and antibody-secreting TIL-B principally located in tertiary lymphoid structures. Some TIL-B also interact directly with tumor cells. Functional analyses reveal TIL-B are responsive to BCR stimulation ex vivo, express activation markers and produce cytokines and immunoglobulins despite reduced expression of the antigen-presenting molecules HLA-DR and CD40. Overall, these data support the concept that ongoing humoral immune responses are generated by TIL-B and help to generate effective anti-tumor immunity at the tumor site.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.129641

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 76 references

Cited by

See all 347

Metadata

Authors
Garaud, S., Buisseret, L., Solinas, C., Gu-Trantien, C., de Wind, A., Van den Eynden, G., Naveaux, C., Lodewyckx, J.-N., Boisson, A., Duvillier, H., Craciun, L., Ameye, L., Veys, I., Paesmans, M., Larsimont, D., Piccart-Gebhart, M., & Willard-Gallo, K.
Venue
JCI Insight
Published
2019-09-19
Volume
4
Issue
18
ISSN
2379-3708 (ISSN-L)
OpenAlex
W2967339341
Cited by
347
References
76
FWCI
12.24
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer. https://app.cochat.ai/papers/10.1172/jci.insight.129641
The paper
Garaud, S., Buisseret, L., Solinas, C., Gu-Trantien, C., de Wind, A., Van den Eynden, G., Naveaux, C., Lodewyckx, J.-N., Boisson, A., Duvillier, H., Craciun, L., Ameye, L., Veys, I., Paesmans, M., Larsimont, D., Piccart-Gebhart, M., & Willard-Gallo, K. (2019). Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer. JCI Insight. https://doi.org/10.1172/jci.insight.129641

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.